Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta

NCT ID: NCT01252355

Last Updated: 2014-06-09

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 534 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2013-04-30

Brief Summary

The primary objective was to demonstrate the effect of teriflunomide, in comparison to placebo, on frequency of Multiple Sclerosis (MS) relapses in patients with relapsing forms of MS who are treated with Interferon-beta (IFN-beta).

The secondary objectives were:

• Assess the effect of teriflunomide, in comparison to placebo, when added to IFN-beta on:

• Disease activity as measured by brain Magnetic Resonance Imaging (MRI)
• Disability progression
• Burden of disease and disease progression as measured by brain MRI
• Evaluate the safety and tolerability of teriflunomide when added to IFN-beta therapy
• Assess the pharmacokinetics of teriflunomide in use in addition to baseline IFN-beta therapy
• Assess associations between variations in genes and clinical outcomes (safety and efficacy)
• Assess other measures of efficacy of teriflunomide such as fatigue and health-related quality of life
• Assess measures of health economics (hospitalization due to relapse, including the length of stay and any admission to intensive care unit)

Detailed Description

The study period per patient was expected to be between 56 and 160 weeks depending on when the patient was randomized and this included the following:

• a screening period up to 4 weeks,
• a treatment period expected to be between 48 and 152 weeks,
• 4-week post rapid elimination follow-up period.

Patients were to continue on treatment until a fixed common end date which was approximately 48 weeks after randomization of the last patient.

For those patients who completed the treatment period, a long term extension study of approximately 1 year (including teriflunomide alone) was initially planned to be proposed.

Conditions

Multiple Sclerosis Relapse

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Teriflunomide 7 mg + IFN-beta

Teriflunomide 7 milligram (mg) once a day concomitantly with IFN-beta therapy.

Group Type: EXPERIMENTAL

Teriflunomide

Intervention Type: DRUG

Film-coated tablet

Oral administration

Interferon-beta (IFN-beta)

Intervention Type: DRUG

Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.

Administration according to the package insert.

Teriflunomide 14 mg + IFN-beta

Teriflunomide 14 mg once a day concomitantly with IFN-beta therapy.

Group Type: EXPERIMENTAL

Teriflunomide

Intervention Type: DRUG

Film-coated tablet

Oral administration

Interferon-beta (IFN-beta)

Intervention Type: DRUG

Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.

Administration according to the package insert.

Placebo + IFN-beta

Placebo (for teriflunomide) once a day concomitantly with IFN-beta therapy.

Group Type: PLACEBO_COMPARATOR

Placebo (for teriflunomide)

Intervention Type: DRUG

Film-coated tablet

Oral administration

Interferon-beta (IFN-beta)

Intervention Type: DRUG

Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.

Administration according to the package insert.

Interventions

Teriflunomide

Film-coated tablet

Oral administration

Intervention Type: DRUG

Placebo (for teriflunomide)

Film-coated tablet

Oral administration

Intervention Type: DRUG

Interferon-beta (IFN-beta)

Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.

Administration according to the package insert.

Intervention Type: DRUG

Other Intervention Names

HMR1726

Eligibility Criteria

Inclusion Criteria

• Patient with relapsing forms of MS treated with IFN-beta
• Stable dose of IFN-beta (approved brand) for at least 6 months prior to randomization
• Disease activity in the 12 months prior to randomization and after first 3 months of IFN-beta treatment (defined by at least 1 relapse supported by EDSS or equivalent neurological examination, or, at least 1 brain or spinal cord MRI with at least one T1 gadolinium enhancing lesion)

Exclusion Criteria

• McDonald criteria for MS diagnosis not met at time of screening visit
• EDSS score greater than (>) 5.5 at randomization visit
• A relapse within 30 days prior randomization
• Persistent significant or severe infection
• Patients must not have used adrenocorticotrophic hormone or systemic corticosteroids for 2 weeks prior to randomization
• Prior or concomitant use of cytokine therapy (except baseline interferons), glatiramer acetate or intravenous immunoglobulins in the 3 months preceding randomization
• Liver function impairment or persisting elevations (confirmed by retest) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or direct bilirubin greater than 2 times the upper limit of normal range (ULN)
• Active hepatitis or hepatobiliary disease or known history of severe hepatitis
• Pregnant or breast-feeding women or those who were planning to become pregnant during the study
• Significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia
• Human Immunodeficiency Virus (HIV) positive
• Known history of active tuberculosis not adequately treated
• Prior use within 2 years preceding randomization or concomitant use of cladribine and mitoxantrone
• Prior use within 6 months preceding randomization or concomitant use of natalizumab, or any other immunosuppressive agents such as azathioprine, cyclophosphamide, cyclosporine, methotrexate, mycophenolate, or fingolimod

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Investigational Site Number 840049

Cullman, Alabama, United States

Investigational Site Number 840005

Cordova, Alaska, United States

Investigational Site Number 840003

Phoenix, Arizona, United States

Investigational Site Number 840011

Oceanside, California, United States

Investigational Site Number 840036

Fort Collins, Colorado, United States

Investigational Site Number 840012

Maitland, Florida, United States

Investigational Site Number 840013

Ormond Beach, Florida, United States

Investigational Site Number 840055

Pompano Beach, Florida, United States

Investigational Site Number 840021

St. Petersburg, Florida, United States

Investigational Site Number 840004

Tampa, Florida, United States

Investigational Site Number 840047

Tampa, Florida, United States

Investigational Site Number 840034

Chicago, Illinois, United States

Investigational Site Number 840037

Elk Grove Village, Illinois, United States

Investigational Site Number 840033

Louisville, Kentucky, United States

Investigational Site Number 840041

Baltimore, Maryland, United States

Investigational Site Number 840028

Baltimore, Maryland, United States

Investigational Site Number 840016

Clinton Township, Michigan, United States

Investigational Site Number 840031

St Louis, Missouri, United States

Investigational Site Number 840030

St Louis, Missouri, United States

Investigational Site Number 840009

Missoula, Montana, United States

Investigational Site Number 840023

Albuquerque, New Mexico, United States

Investigational Site Number 840015

New York, New York, United States

Investigational Site Number 840027

Charlotte, North Carolina, United States

Investigational Site Number 840006

Bismarck, North Dakota, United States

Investigational Site Number 840007

Fargo, North Dakota, United States

Investigational Site Number 840046

Dayton, Ohio, United States

Investigational Site Number 840017

Toledo, Ohio, United States

Investigational Site Number 840043

Tulsa, Oklahoma, United States

Investigational Site Number 840002

Nashville, Tennessee, United States

Investigational Site Number 840040

Round Rock, Texas, United States

Investigational Site Number 840020

San Antonio, Texas, United States

Investigational Site Number 840032

Vienna, Virginia, United States

Investigational Site Number 032002

Argentina, , Argentina

Investigational Site Number 032003

Buenos Aires, , Argentina

Investigational Site Number 032004

Caba, , Argentina

Investigational Site Number 036008

Bedford Park, , Australia

Investigational Site Number 036005

Chatswood, , Australia

Investigational Site Number 036001

Heidelberg West, , Australia

Investigational Site Number 036004

Kogarah, , Australia

Investigational Site Number 036010

New Lambton, , Australia

Investigational Site Number 040001

Graz, , Austria

Investigational Site Number 040004

Linz, , Austria

Investigational Site Number 056005

Charleroi, , Belgium

Investigational Site Number 056004

Ghent, , Belgium

Investigational Site Number 056003

Hasselt, , Belgium

Investigational Site Number 056006

La Louvière, , Belgium

Investigational Site Number 056002

Leuven, , Belgium

Investigational Site Number 056001

Sijsele-Damme, , Belgium

Investigational Site Number 056007

Wilrijk, , Belgium

Investigational Site Number 076009

Joinville, , Brazil

Investigational Site Number 076012

Passo Fundo, , Brazil

Investigational Site Number 076003

Porto Alegre, , Brazil

Investigational Site Number 076007

São Paulo, , Brazil

Investigational Site Number 076013

São Paulo, , Brazil

Investigational Site Number 124005

Calgary, , Canada

Investigational Site Number 124004

Edmonton, , Canada

Investigational Site Number 124003

Gatineau, , Canada

Investigational Site Number 124006

Kingston, , Canada

Investigational Site Number 124007

Montreal, , Canada

Investigational Site Number 124008

Ottawa, , Canada

Investigational Site Number 124002

Regina, , Canada

Investigational Site Number 124001

Sherbrooke, , Canada

Investigational Site Number 124009

Winnipeg, , Canada

Investigational Site Number 152003

Santiago, , Chile

Investigational Site Number 152004

Santiago, , Chile

Investigational Site Number 152005

Viña del Mar, , Chile

Investigational Site Number 170001

Barranquilla, , Colombia

Investigational Site Number 170005

Bogotá, , Colombia

Investigational Site Number 170007

Bogotá, , Colombia

Investigational Site Number 170009

Medellín, , Colombia

Investigational Site Number 208002

Aarhus C, , Denmark

Investigational Site Number 233002

Tallinn, , Estonia

Investigational Site Number 233001

Tartu, , Estonia

Investigational Site Number 246003

Helsinki, , Finland

Investigational Site Number 246006

Hyvinkää, , Finland

Investigational Site Number 246004

Oulu, , Finland

Investigational Site Number 246002

Pori, , Finland

Investigational Site Number 246001

Turku, , Finland

Investigational Site Number 250003

Besançon, , France

Investigational Site Number 250010

Clermont-Ferrand, , France

Investigational Site Number 250002

Lyon, , France

Investigational Site Number 250004

Montpellier, , France

Investigational Site Number 250001

Nancy, , France

Investigational Site Number 250006

Nantes, , France

Investigational Site Number 276009

Bad Mergentheim, , Germany

Investigational Site Number 276020

Bamberg, , Germany

Investigational Site Number 276003

Bayreuth, , Germany

Investigational Site Number 276015

Berlin, , Germany

Investigational Site Number 276016

Berlin, , Germany

Investigational Site Number 276021

Berlin, , Germany

Investigational Site Number 276012

Bonn, , Germany

Investigational Site Number 276005

Dresden, , Germany

Investigational Site Number 276032

Düsseldorf, , Germany

Investigational Site Number 276018

Erbach im Odenwald, , Germany

Investigational Site Number 276004

Erlangen, , Germany

Investigational Site Number 276028

Freiburg im Breisgau, , Germany

Investigational Site Number 276006

Giessen, , Germany

Investigational Site Number 276010

Hamburg, , Germany

Investigational Site Number 276022

Hennigsdorf, , Germany

Investigational Site Number 276024

Kassel, , Germany

Investigational Site Number 276001

Leipzig, , Germany

Investigational Site Number 276013

Mainz, , Germany

Investigational Site Number 276023

Minden, , Germany

Investigational Site Number 276002

Münster, , Germany

Investigational Site Number 276031

Rostock, , Germany

Investigational Site Number 276008

Wiesbaden, , Germany

Investigational Site Number 276026

Wuppertal, , Germany

Investigational Site Number 300002

Athens, , Greece

Investigational Site Number 300001

Athens, , Greece

Investigational Site Number 300003

Heraklion, , Greece

Investigational Site Number 300006

Thessaloniki, , Greece

Investigational Site Number 348002

Budapest, , Hungary

Investigational Site Number 348006

Budapest, , Hungary

Investigational Site Number 348010

Budapest, , Hungary

Investigational Site Number 348009

Eger, , Hungary

Investigational Site Number 348003

Esztergom, , Hungary

Investigational Site Number 348001

Szeged, , Hungary

Investigational Site Number 348005

Székesfehérvár, , Hungary

Investigational Site Number 348007

Zalaegerszeg, , Hungary

Investigational Site Number 380009

Catania, , Italy

Investigational Site Number 380002

Cefalù, , Italy

Investigational Site Number 380003

Fidenza, , Italy

Investigational Site Number 380004

Gallarate, , Italy

Investigational Site Number 380012

Montichiari, , Italy

Investigational Site Number 380010

Napoli, , Italy

Investigational Site Number 380011

Napoli, , Italy

Investigational Site Number 380006

Padua, , Italy

Investigational Site Number 380005

Roma, , Italy

Investigational Site Number 380008

Roma, , Italy

Investigational Site Number 380014

Verona, , Italy

Investigational Site Number 440002

Kaunas, , Lithuania

Investigational Site Number 440004

Klaipėda, , Lithuania

Investigational Site Number 440003

Šiauliai, , Lithuania

Investigational Site Number 528001

Breda, , Netherlands

Investigational Site Number 528005

Nieuwegein, , Netherlands

Investigational Site Number 528002

Sittard-Geleen, , Netherlands

Investigational Site Number 528006

Venray, , Netherlands

Investigational Site Number 578002

Tønsberg, , Norway

Investigational Site Number 620001

Amadora, , Portugal

Investigational Site Number 620002

Coimbra, , Portugal

Investigational Site Number 620004

Coimbra, , Portugal

Investigational Site Number 620003

Setúbal, , Portugal

Investigational Site Number 643012

Kaluga, , Russia

Investigational Site Number 643007

Kazan', , Russia

Investigational Site Number 643001

Kemerovo, , Russia

Investigational Site Number 643013

Moscow, , Russia

Investigational Site Number 643006

Nizhny Novgorod, , Russia

Investigational Site Number 643004

Nizhny Novgorod, , Russia

Investigational Site Number 643015

Novosibirsk, , Russia

Investigational Site Number 643010

Rostov-on-Don, , Russia

Investigational Site Number 643009

Rostov-on-Don, , Russia

Investigational Site Number 643011

Saint Petersburg, , Russia

Investigational Site Number 643018

Saint Petersburg, , Russia

Investigational Site Number 643003

Saint Petersburg, , Russia

Investigational Site Number 643017

Saint Petersburg, , Russia

Investigational Site Number 643002

Saint Petersburg, , Russia

Investigational Site Number 643016

Samara, , Russia

Investigational Site Number 643005

Smolensk, , Russia

Investigational Site Number 643014

Yaroslavl, , Russia

Investigational Site Number 703002

Martin, , Slovakia

Investigational Site Number 703001

Trnava, , Slovakia

Investigational Site Number 410002

Goyang-si, , South Korea

Investigational Site Number 410004

Seoul, , South Korea

Investigational Site Number 410001

Seoul, , South Korea

Investigational Site Number 724001

Barcelona, , Spain

Investigational Site Number 724002

Barcelona, , Spain

Investigational Site Number 724009

Córdoba, , Spain

Investigational Site Number 724003

Girona, , Spain

Investigational Site Number 724004

Madrid, , Spain

Investigational Site Number 724005

Madrid, , Spain

Investigational Site Number 724007

Murcia, , Spain

Investigational Site Number 724008

Seville, , Spain

Investigational Site Number 752004

Gothenburg, , Sweden

Investigational Site Number 752003

Stockholm, , Sweden

Investigational Site Number 752001

Stockholm, , Sweden

Investigational Site Number 788002

Manouba, , Tunisia

Investigational Site Number 788005

Monastir, , Tunisia

Investigational Site Number 788004

Sfax, , Tunisia

Investigational Site Number 788006

Tunis, , Tunisia

Investigational Site Number 826008

Birmingham, , United Kingdom

Investigational Site Number 826005

Leeds, , United Kingdom

Investigational Site Number 826006

Liverpool, , United Kingdom

Investigational Site Number 826003

London, , United Kingdom

Investigational Site Number 826004

Plymouth, , United Kingdom

Investigational Site Number 826001

Salford, , United Kingdom

Countries

United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; Colombia; Denmark; Estonia; Finland; France; Germany; Greece; Hungary; Italy; Lithuania; Netherlands; Norway; Portugal; Russia; Slovakia; South Korea; Spain; Sweden; Tunisia; United Kingdom

Other Identifiers

2010-023172-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1115-2414

Identifier Type: OTHER

Identifier Source: secondary_id

EFC6058

Identifier Type: -

Identifier Source: org_study_id